Endocrinology, Diabetology and Andrology Unit, Humanitas Clinical and Research Center, IRCCS, Rozzano, Milan, Italy.
Department of Medical-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Latina, Italy.
J Endocrinol Invest. 2020 Nov;43(11):1561-1569. doi: 10.1007/s40618-020-01237-1. Epub 2020 Apr 2.
Vertebral fractures (VFs) were described in elderly patients with heart failure (HF) whereas their prevalence and determinants in younger HF patients are still unknown. This study aimed at assessing whether secondary hyperparathyroidism (SHPT) may influence the risk of VFs in middle-aged patients with HF.
84 patients (44 males, median age 48.5 years, range 43-65) with HF were prospectively evaluated at the baseline and after 36-month follow-up for bone mineral density (BMD) and VFs by quantitative morphometry on chest X-rays. Serum PTH, calcium, 25-hydroxyvitamin D and 24-h-urinary calcium were evaluated at the baseline and every 6-12 months during the study period.
At baseline, SHPT, hypovitaminosis D and VFs were found in 43 patients (51.2%), 73 patients (86.9%) and 29 patients (34.5%), respectively. SHPT was associated with VFs at baseline [inverse probability-weighted (ipw) odds ratio (OR) 12.2, p < 0.001]. Patients were treated with vitamin D3 alone (56%), vitamin D3 plus calcium carbonate (21.4%), calcitriol alone (4.8%), bisphosphonates plus vitamin D3 (8.3%) or a combination of bisphosphonates, vitamin D3 and calcium carbonate (9.5%). At the end of follow-up, hypovitaminosis D was corrected in all patients, whereas 19/84 patients (22.6%) had persistent SHPT. During the follow-up, 16 patients developed incident VFs which resulted to be associated with baseline SHPT (ipw OR 55.7, p < 0.001), even after adjusting from BMD change from baseline to follow-up (ipw OR 46.4, p < 0.001).
This study provides a first evidence that SHPT may be a risk factor for VFs in middle-aged patients with HF.
在老年心力衰竭(HF)患者中描述了椎体骨折(VF),而在年轻 HF 患者中,其患病率和决定因素仍不清楚。本研究旨在评估继发性甲状旁腺功能亢进症(SHPT)是否会影响中年 HF 患者发生 VF 的风险。
84 名(44 名男性,中位年龄 48.5 岁,范围 43-65 岁)HF 患者前瞻性评估基线和 36 个月随访时的骨密度(BMD)和 VF,采用胸部 X 射线定量形态计量学方法。在基线和研究期间每 6-12 个月评估血清甲状旁腺素(PTH)、钙、25-羟维生素 D 和 24 小时尿钙。
基线时,43 名(51.2%)患者存在 SHPT、维生素 D 缺乏症和 VF,73 名(86.9%)患者存在维生素 D 缺乏症,29 名(34.5%)患者存在 VF。基线时,SHPT 与 VF 相关(逆概率加权(ipw)比值比(OR)12.2,p<0.001)。患者接受维生素 D3 单独治疗(56%)、维生素 D3 加碳酸钙(21.4%)、骨化三醇单独治疗(4.8%)、双膦酸盐加维生素 D3 治疗(8.3%)或双膦酸盐、维生素 D3 和碳酸钙联合治疗(9.5%)。随访结束时,所有患者均纠正了维生素 D 缺乏症,而 84 名患者中有 19 名(22.6%)仍存在持续性 SHPT。随访期间,16 名患者发生新发 VF,其与基线时的 SHPT 相关(ipw OR 55.7,p<0.001),即使在调整了从基线到随访的 BMD 变化后,结果仍具有统计学意义(ipw OR 46.4,p<0.001)。
本研究首次提供了证据表明,SHPT 可能是中年 HF 患者 VF 的危险因素。